http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
당뇨병성 신증 및 신증후군 환자의 혈중 Lp ( a )
유순집,윤건호,이광우,손호영,권혁호,우제영,차봉연,강성구 한국지질학회 1993 韓國脂質學會誌 Vol.3 No.1
There are intimate relationship between dyslipidemia and atherosclerosis. The incidence and the mortality of cardiovascular disease increased in proteinuric disorder such as diabetic nephropathy and nephrotic syndrome. Recently there were evidence that increased concentrations of serum Lp(a), which is independent risk factor to atherosclerotic cardiovascular and cerebrovascular disease, in proteinuric disorder. We intended to search and identify the mechanism of altered concentrastions of Lp(a) in proteinuric disorder via measuring serum Lp(a) concentrations with ELIZA in 26 patients with diabetic nephropathy, 20 patients with nephrotic syndrome and 59 control. The results were as follows 1) There were significantly increased amounts of 24 hour urine protein in diabetic nephropathy group[DN](6.0±4.5 g/㎗) and nonremission group [R-](4.8±1.8 g/㎗) of nephrotic syndrome compared to remission group[R+](0.7±0.4 g/㎗) (p$lt;0.05) and significantly decreased serum albumin level in [R-](2.2±1.3g/㎗) compared to [DN](3.1±0.6g/㎗) and [R+](3.4±0.8g/㎗) (p$lt;0.05) and significantly decreased serum protein level in [R-](6.6±0.7g/㎗) compared to [R+](5.1±1.2g/㎗) (p$lt;0.05). 2) There were significantly increased level of total cholesterol and LDL-cholesterol in [R-](327.8±141.3 g/㎗ & 234.1±129.7㎎/㎗) compared to [DN](246.6±66.4 ㎎/㎗) (p$lt;0.05), but no significant difference in triglyceride and HDL-cholesterol among [R-]. [R+] and [DN](p$gt;0.05). 3) There were significantly increased concentration of serum Lp(a) in [DN] [median 36.3 (range 4.0-164.0 ㎎/㎗)], [R+] [28.3 (15.0-145.0 ㎎/㎗)]. [R-] [130.5 (10.1-177.0 ㎎/㎗)] compared to control [median 13.0 (range 1.0-70.0㎎/㎗)](p$lt;0.05). And there were significant difference in serum Lp (a) concentration of [R-] compared to [DN] and [R+](p$lt;0.05). 4) There were significant correlations in serum Lp(a) concentrations with serum albumin, total cholesterol and LDL-cholesterol, but no significant correlations in age, sex, fasting blood sugar, serum creatinine, triglyceride, HDL-cholesterol and 24hr urine protein in proteinuric disorder. There were statistically significant increased concentrations of serum Lp(a) in proteinuric disorder compared to control group and the concentrations were variable according to kind and state of disease. The results suggested that increased hepatic synthesis of Lp(a) would be one of the mechanism of increased concentrations of serum Lp(a) in these proteinuric disorder and it would be relate to decreased level of serum albumin.
유순집 사단법인 한국당뇨협회 2003 당뇨 Vol.166 No.-
인슐린 치료를 필요로 하는 당뇨병 환자에서는 당뇨병성 합병증의 발생을 예방하거나 합병증이 진행된 경우에는 기존의 고식적인 치료로 만족할 만한 효과를 거두기가 어려워 이상적인 치료 방법에 대한 기대가 높은 상태이다. 특히 췌도이식 대상자는 급증하고 있으나 공급 가능한 췌장은 한정되어 있어 이식에 필요한 췌도는 절대적인 부족 상태로 오직 일부 제 1형 당뇨병 환자에서만 제한적으로 췌도이식이 적용 가능하다. 따라서 충분한 췌도 이식원을 확보할 수 있는 췌도 이식원의 개발은 췌도이식의 가장 큰 목표라 할 수 있다. 본 난에서는 당뇨병 치료에서 시험관내 및 생체실험에서 줄기세포의 현황과 줄기세포를 이용하여 당뇨병을 극복하고자 하는 연구의 성과와 이에 따른 새로운 치료법에 대한 최근 내용을 고찰해 보고자 한다.
유순집,장상아,손태서,권혁상,이정민,문성대,Pieter Proot,Paldánius Päivi Maria,윤건호 대한당뇨병학회 2021 Diabetes and Metabolism Journal Vol.45 No.6
We assessed the glycaemic durability with early combination (EC; vildagliptin+metformin [MET], n=22) versus MET monotherapy (n=17), among newly-diagnosed type 2 diabetes mellitus (T2DM) enrolled (between 2012 and 2014) in the VERIFY study from Korea (n=39). Primary endpoint was time to initial treatment failure (TF) (glycosylated hemoglobin [HbA1c] ≥7.0% at two consecutive scheduled visits after randomization [end of period 1]). Time to second TF was assessed when both groups were receiving and failing on the combination (end of period 2). With EC the risk of initial TF significantly reduced by 78% compared to MET (n=3 [15%] vs. n=10 [58.7%], P=0.0228). No secondary TF occurred in EC group versus five patients (29.4%) in MET. Patients receiving EC treatment achieved consistently lower HbA1c levels. Both treatment approaches were well tolerated with no hypoglycaemic events. In Korean patients with newly diagnosed T2DM, EC treatment significantly and consistently improved the long-term glycaemic durability as compared with MET.